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the intestine (more physiologically into the duodenum) should be carried out only after
improving the general condition of patients and compensating for the function of vital
organs and systems.
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Introduction: Platinum-based chemotherapy (P) is the main standard perioperative
treatment (FLOT, ECF) in locally advanced gastric carcinoma (LAGC) and in some
adjuvant schemas (CAPOX). Furthermore the first line treatment is P chemotherapy.
Currently, there is no evidence supporting P treatment in the first line setting after
relapse in patients that were previously treated with P schemas in the locally advanced
setting. No time cut off was suggested to indicate a possibly P sensitivity.
Methods: We analysed all the patients with gastric adenocarcinoma treated in 2 centers
from 2011 to 2018. We selected only patients with LAGC treated with perioperative or
adjuvant P based chemotherapy, in which disease relapse occurred with first-line che-
motherapy. Time from last perioperative or adjuvant P based chemotherapy to relapse
(platinum-free interval PFI), was calculated. Median progression-free survival and
median overall survival from relapse (mPFS and mOS).
Results: From a total of 602 patients, only 29 met inclusion criteria. Mean age was 58y,
43% were female, 98% had PS 0-1, 52% were localized initially in gastric body, 56% were
T4a-T4b and 82% were Nþ at diagnosis, 25% had intestinal histology, 21 had regression
grade 2 (10–50% residual tumour). Median PFI was 14.8m (0.8 -89.2). 64% received P as
first line and 36% received taxane based chemothepy (T). According to PFI, 21% had 0-
6m PFI, 14% had 6-9m PFI, 4% had 9-12m PFI, 14% had 12-18m PFI, 14% had 18-24
PFI, had 32% had PFI>24m. Median PFS since relapse for all patients was 8.8m. There
was no difference in mPFS between P or T chemotherapy: 11.5 (95%CI 4.5-17.1) vs
5.7(95%CI 4.5-6.8), respectively, p¼ 0.06. A better mPFS was observed for P treated
patients when PFI was higher than 9 months: 11.1m vs 4.3m, for P vs T patients respec-
tively, p¼ 0.48, HR¼ 4.8. This benefit was observed from PFI>9 to PFI>18m. For
PFI>24m no analysis could be done because all patients received P based chemotherapy.
No differences were detected between P and T if PFI was lower than 9m. Median OS since
relapse for all patients was 11.7m. There was no difference in mPFS between P or T che-
motherapy: 16.1 (95%CI 6.4-25.8) vs 9.1 (95%CI 2.5-15.7), respectively, p¼ 0.08. Albeit
an important numerical benefit in mOS observed for P treated patients when PFI was
higher than 9 months, it was no statistically significant: 16.1m (95%CI 6.4-25.8) vs 9.1
(95%CI 2.5-15.7) p¼ 0.08, for P vs T, respectively. There were no differences in mPFS nor
mOS according to histology subtype between P vs T. Due to the small number of patients
with reported pathologic response no association could be made.
Conclusion: In this highly selected population, platinum sensitivity could be observed
with platinum free intervals higher than 9 months. The main study limitation is the
small patient sample. Larger studies are encouraged.
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Introduction: Surgery is the mainstay of curative-intent treatment for stage IB-III GCs.
However, in the Western world, 40-60% of patients (pts) relapse after surgical resection
and the absolute survival benefit of adjunctive modalities is limited to 6-14% at 5 years.
Thus, there is an unmet need for reliable prognosticators capable of guiding treatment
decision in daily practice and risk-stratification in clinical trials to maximize the risk-
benefit ratio of available approaches.
Methods: Electronic medical records of pts undergoing surgical resection for T2-4 and/
or lymph node-positive GCs from January, 2010 to July 31, 2018, at the Modena
Cancer Centre were reviewed. Post-surgery clinical, pathologic and biochemical varia-
bles of interest were retrieved. Laboratory variables initially recorded as continuous
parameters were later dichotomized using the ROC analysis. The impact of the col-
lected covariates on the risk of recurrence and on survival was evaluated through logis-
tic regression and Cox proportional hazards model, respectively.
Results: A total of 207 GCs underwent curative resection at our Institution over the study
period and 157 pts had all available data for the analysis. Among the latter, 51% of pts
were female and the median age at diagnosis was 74 years (range 32-94). 93% of pts had a
non-cardia GC and 52% presented with stage I-II disease. 47% of pts received adjuvant
chemotherapy. The median follow-up time was 57 months (IC95% 34-89). Disease recur-
rence was recorded in 36% of pts. Median relapse-free survival (RFS) and overall survival
(OS) were 28 and 33 months, respectively. The following parameters were linked to an
increased risk of relapse after surgical resection: vascular invasion (OR 4.47, P 0.19 (OR
9.48; P< 0.0001), eosinophil count> 110/mmc (OR 2.92; P¼ 0.013). At the multivariate
analysis for RFS, ECOG PS 1, vascular invasion and lymph node ratio> 0.19 were
shown to be independent negative prognostic factors. With regards to the impact on OS,
ECOG PS 1 (P 0.19 (P¼ 0.0046) and platelet-to-lymphocyte ratio> 124 (P¼ 0,0293)
were significantly associated with a poorer outcome.
Conclusion: Our study confirms the prognostic value of previously described clinico-
pathologic factors and identifies eosinophils and platelet-to-lymphocyte ratio as inde-
pendent predictors of outcome in a Western cohort of resected GCs from a tertiary
cancer centre. The promising role of immune-inflammatory markers deserves prospec-
tive validation in larger studies in order to improve the accuracy of currently available
prediction tools.
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Introduction: Pancreatic cancer (PC) is one of the most aggressive and deadly malignan-
cies. Gemcitabine (GEM) is the key agent in the first-line standard regimen for advanced
PC, which is mostly diagnosed at advanced stage and unsuitable for curative resection.
The objective response rate (ORR) and median progression-free survival (PFS) of various
GEM-based regimens are still unsatisfactory. Therefore, development of new therapeutic
modalities, including immunotherapy, is needed. This study aimed to investigate the effi-
cacy, safety and clinical benefit of combination personalized immunotherapy with GEM
and radiotherapy in locally advanced and metastatic PC patients.
Methods: Three locally advanced unresectable and seven metastatic PC patients
received at least two cycles of GEM (1000mg/m2 on day 1 and day 6) and radiotherapy
combined with neoantigen-induced DC vaccination on day 7 and cytotoxic T lympho-
cyte transfer from day 12 to 15 (repeated every 21 days). The locally advanced unresect-
able PC patients received stereotactic body radiotherapy (SBRT) with a total amount of
50-66Gy during the first cycle. For metastatic patients, their partial lesions received low
dose radiation (0.5Gy bid*2days ) on day 10 and 11 in each cycle.
Results: Two cases with partial remission (PR), 5 with stable disease (sd), and 3 with
progressive disease (PD) were observed. The disease control rate (DCR) was 70%.
Median progression-free survival (PFS) was 6.4 months. After the first treatment cycle,
the total effectiveness in terms of pain easement and increasing appetite were 100% and
66.7%, respectively. Haematotoxicities with a 40% incidence rate were the most com-
mon adverse drug reactions. Two patients had grade 1 to 2 neutropenia and two had
grade 3 to 4 thrombocytopenia. Three patients suffered grade 1 to 2 gemcitabine-
induced skin rash. No treatment-related mortality occurred.
Conclusion: Neoantigen reactive T cells combined with chemoradiotherapy demon-
strated an acceptable response and safety in advanced pancreatic cancer patients.
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Introduction: Gender-specific differences in gastric cancer are important in individu-
alized medicine. There are few studies on gender differences in gastric cancer.
Therefore, this study was conducted to investigate the differences in the clinicopatho-
logic characteristics according to gender in gastric cancer.
Methods: We retrospectively reviewed 1113 patients who underwent surgical treatment
for gastric neoplasm between January 2011 and December 2015. We analyzed 903
patients who underwent surgery for gastric adenocarcinoma without previous gastric
surgery or gastric tumor treatment.
Results: Among the 903 patients, the mean age was 60.4 years, and 69.7% of patients
were men. Early gastric cancer was significantly higher in female than male patients
(70.8% vs 61.4%, p¼ 0.007). In addition, the number of patients over 65 years was sig-
nificantly higher in female patients (46.7% vs 36.9%, p¼ 0.006). Undifferentiated can-
cers were also significantly more common in women (75.2% vs 52.1%, p< 0.001).
However, there was no significant differences in size (more than 40mm), vertical loca-
tion, TNM stage, the presence of lymph node metastasis, and the presence of lympho-
vascular invasion. Multivariate analysis showed that the percentage of patients over 65
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